Get started
Author

Akihide Wakamatsu

Observed names: A. Wakamatsu, Wakamatsu, Akihide
ORCID: 0000-0001-8551-8324
Observed ORCID: 0000-0001-8551-8324
OpenAlex ID: A5038807255
Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: A safety pharmacology study
2009 · Akihide Wakamatsu, Shunji Nomura, et al. · Journal of Pharmacological and Toxicological Methods · 15
Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.
2013 · Akihide Wakamatsu, Kazuo Aoki, et al. · Europe PMC (PubMed Central) · 13
The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
2015 · Takashi Ohnishi, Ryoko Nakagawa, et al. · Neuropsychiatric Disease and Treatment · 10
PDF
Clinical benefit of second-generation long-acting injectable antipsychotics in preventing re-hospitalization in patients with schizophrenia: A real-world study in Japan
2023 · Mami Kasahara-Kiritani, Yosuke Saga, et al. · Asian Journal of Psychiatry · 8
The Effects of Paliperidone Palmitate 1 Month on the Employment Status and Social Functioning of Patients with Schizophrenia.
2020 · Takashi Ohnishi, Hisanori Kobayashi, et al. · PubMed Central · 8
Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression
2022 · Takashi Ohnishi, Akihide Wakamatsu, et al. · Psychiatry and Clinical Neurosciences · 6
Budget impact analysis of long acting injection for schizophrenia in Japan
2020 · Mami Kasahara-Kiritani, Amish Chaturvedi, et al. · Journal of Medical Economics · 6
PDF
Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database
2024 · Chih‐Lin Chiang, Madoka Chinen, et al. · Neuropsychopharmacology Reports · 5
PDF
Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
2021 · Takashi Ohnishi, Akihide Wakamatsu, et al. · Neuropsychiatric Disease and Treatment · 5
PDF
Understanding anhedonia in major depressive disorder in Japan: epidemiology and unmet needs from patients’ and physicians’ perspectives
2025 · Mami Kasahara-Kiritani, Tadafumi Kato, et al. · BMC Psychiatry · 4
PDF
Budget impact analysis of long-acting injections for the treatment of Schizophrenia in Japan
2025 · Mami Kasahara-Kiritani, Chu-chu Sheng, et al. · Asian Journal of Psychiatry · 3
Reporting Frequency of Antipsychotics‐Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan
2025 · Yosuke Saga, Hiroshi Horio, et al. · Neuropsychopharmacology Reports · 2
PDF
A descriptive analysis of spontaneous reports of antipsychotic‐induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database
2023 · Yosuke Saga, Chih‐Lin Chiang, et al. · Neuropsychopharmacology Reports · 2
XEPLION® Aqueous Suspension for IM Injection
2016 · Akihide Wakamatsu, Osamu Soga · Drug Delivery System · 2
PDF
Treatment Persistence of Paliperidone Palmitate 3‐Month in Patients With Schizophrenia: A Japan Medical Data Center Claims Database Analysis
2025 · Akihide Wakamatsu, Madoka Chinen, et al. · Neuropsychopharmacology Reports · 1
PDF
P.3.d.014 Efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia: a 13-week double-blind study
2013 · A. Wakamatsu, N. Takahashi, et al. · European Neuropsychopharmacology · 1
Evaluation of Efficacy and Safety of Paliperidone Palmitate with Schizophrenia: Subpopulation Analysis of Japanese Patients in the 13-Week, Double-Blind, Randomized, Placebo-Controlled Asian Study
2013 · Akihide Wakamatsu, Nagahide Takahashi, et al. · Progress in medicine · 1
Antipsychotic-induced Extrapyramidal Symptoms and Tardive Dyskinesia: Analysis Based on a Spontaneous Reporting System Database in Japan
2025 · *Yosuke Saga, Hiroshi Horio, et al. · The International Journal of Neuropsychopharmacology
PDF
Treatment Persistence of Paliperidone Palmitate 3-month in Patients With Schizophrenia -an Analysis of Japan Medical Data Center Claims Database
2025 · *Madoka Chinen, Yosuke Saga, et al. · The International Journal of Neuropsychopharmacology
PDF
Factors Associated With Continuation of Paliperidone Palmitate 1-month Formulation Monotherapy in Patients With Schizophrenia
2025 · *Tatsuro Marumoto, Hiroshi Horio, et al. · The International Journal of Neuropsychopharmacology
Interim Report of a Post-marketing Surveillance of Paliperidone Palmitate 3-month Formulation in Japanese Patients With Schizophrenia
2025 · *Tatsuro Marumoto, Yosuke Saga, et al. · The International Journal of Neuropsychopharmacology
PDF
The effects of COVID-19 pandemic on mental health in office workers telecommuting in Japan: Cross-Sectional Survey Study (Preprint)
2022 · Takashi Ohnishi, Akihide Wakamatsu
Reports regarding adverse drug reaction in pharmacovigilance of paliperidone palmitate (Xeplion
2019 · Akihide Wakamatsu · Asian College of Neuropsychopharmacology
パリペリドンパルミチン酸エステル(ゼプリオン水懸筋注),パリペリドン徐放錠(インヴェガ)及びリスペリドン持効性注射剤(リスパダールコンスタ)の製造販売後調査における死亡発生率の比較
2017 · Akihide Wakamatsu, Imai Keiko, et al.
P.3.d.039 Paliperidone extended-release monotherapy suggested greater improvement of social functioning than polypharmacy in clinical practice
2014 · A. Wakamatsu, T. Ohnishi, et al. · European Neuropsychopharmacology
Works count: 31
Citation count: 92
H-index: 6
I10-index: 3
Year
Topic
Type